Securing comparator drugs in the EU is a complex process shaped by availability constraints, regulatory expectations, and competitive market behavior. But if we have the right planning, strong ...

In today’s ACT Brief, we examine the growing challenges of sourcing comparator drugs across the EU, highlight a new AI-driven ...

A Type B meeting between the FDA and Plus Therapeutics offered clarity and direction for the next steps in development of ...

Polyrizon Ltd. Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a pre-clinical-stage biotechnology company developing intranasal protective solutions today announced positive results from ...

Craig Morgan outlines why comparator clinical trials are useful and provides points to consider to ensure the best outcome. In clinical trials, a comparator drug (defined as ‘an investigational or ...

IM1240 demonstrated improved safety in a toxicology study at doses up to 300-fold higher than a non-capped comparator ...

On track to define optimal dosing interval and advance manufacturing scale up of REYOBIQ for pivotal trial readiness in late ...

Using a single microcontroller port to drive a multi-digit LED display to help engineers with those last-minute design ...

Newly diagnosed patients with KRAS G12C-mutant advanced or metastatic nonsquamous NSCLC will be enrolled in the trial.

The Financial Conduct Authority (FCA) has published updated proposals to its Value for Money (VFM) Framework consultation.

After unsheathing just a few months ago, Ollin Biosciences’ next-gen bispecific antibody cleared more disease faster than ...